“a strong trend”

Interestingly, high CD4 + T-cells ΔPSI >5 was found to correlate with a strong trend of improved progression-free survival (3.9-fold) (10.8 vs. 2.8 months; P=0.07) and overall survival (3-fold) (34.5 vs. 11.5 months; P=0.09) in ICI-treated patients.

CDK4/6 inhibitors improved iDFS (HR 0.80; 95% CI: 0.67–0.96; p = 0.01), while a strong trend toward improved DRFS was observed (HR 0.79; 95% CI: 0.61–1.02; p = 0.07), suggesting a potential clinically relevant benefit that requires longer follow-up to confirm.

The area under the glucose curve over the 75 min examination period showed a strong trend towards decreasing in Npff −/− versus WT mice for both genders ( p = 0.07) ( Figure 1 J, L).

No significant alterations in cortical bone volume were observed, although there was a strong trend towards increased cortical bone volume following administration of 0.6 g/L losartan ( P = 0.07) and a significant increase in cortical thickness ( P < 0.001) ( Fig. 2 G–H).

[ 81 ] reported a strong trend ( p = 0.07) for oral rehydration to increase exercise capacity compared with intravenous rehydration in recovery from hypohydration (4% body mass).

We also identified a strong trend for a gradual divergence between genotypes, starting on the second trial, for the time in port metric (genotype effect, CTRL > Ex3d, F (1,27) = 3.51, p = 0.07; Fig. 8 A ).

There was a strong trend for female offspring of dex-treated mothers to have less pericyte coverage compared with female offspring from veh-treated mothers ( P < 0.07) ( Fig. 2b, 2d, 2e ).

A strong trend for improved grip strength was further demonstrated with RAP in vehicle-treated ( p = 0.07 by t-test, Fig. 3 c), but not in rt-PA-treated animals.

Two-way repeated-measures ANOVA with group (saline-vehicle, cocaine-vehicle, and cocaine-RO5166017) as between subjects and test (first trial and last trial of extinction) as within subjects was conducted to analyze the effect of RO5166017 on extinction, showing an effect of group ( F 2,32 = 3.83, P < .05) and test ( F 2,32 = 4.64, P < .05) and a strong trend of interaction of group × test ( F 2,32 = 2.89, P = .07).

Both furosemide naïve and recipients of chronic oral furosemide experienced an increase in renal medullary T2* signal intensities after the 20 mg IV furosemide stimulus albeit with a strong trend toward attenuation of the response in those chronically prescribed oral furosemide (p = 0.07).

EMG activity There was a strong trend towards an increased EMG activity during the fatiguing contractions (time main effect; F 1,9 = 9.07; η 2 = 0.4, P = 0.07) but there was no difference between the tasks (task×muscle; F 2,18 = 2.5; η 2 = 0.4, P = 0.87).

However, controllers had a strong trend of higher proportions of CCR5-expressing CD8+ T cells in comparison to HCs ( P =0.07, Figure 1D ).

A mixed repeated measures ANOVA, including only TD participants, showed a near-significant time x stimulation interaction (F(2,25) = 2.89, p = 0.07), demonstrating a strong trend toward a decrease in tremor severity at post-assessment for both the medial and lateral stimulation groups (Fig. 3 ).

The general pattern of reduced lactate accumulation with GPLC is apparent to some degree in the three study groups, but only the 1.5 g/d group displayed a strong trend (p = 0.07) for statistically significant reduction in absolute blood lactate levels at 14 min post sprints.

The nighttime levels were non-significant, but the correlation value showed a strong trend in the expected direction (p=0.07).

Bonferroni post‐hoc analysis revealed a strong trend on Day 7, with the LAD group showing higher E/E' compared to the LAD+CARD group (LAD: 25.81 ± 8.27; LAD+CARD: 17.26 ± 6.59, p = 0.07).

Neither placebo nor METABO administration affected concentrations of blood lipids, including cholesterol, HDL, LDL, cholesterol/HDL ratio and TAG, although there was a strong trend (p < 0.07) for TAG concentrations to decrease more in the METABO group (-15.9%) compared to the placebo group (-2.6%).

Our data support this mechanism, as patients in the MAS group had a significantly higher percentage of CD8 + T cells ( P = 0.004), and an elevated CD8 + T-cell percentage showed a strong trend toward being a risk factor for MAS in the multivariate analysis ( P = 0.0703).

Quantitative analysis of [ 18 F]MPPF uptake in the brain was increased in mice lacking functional Slc6a8 with a strong trend towards statistical significance ( p = 0.0709; WT, 0.304 ± 0.066%ID/cc, n = 13; Slc6a8 -/y , 0.358 ± 0.073%ID/cc, n = 11) (Fig. 8 A).

Lipid Peroxidation DHA+ARA supplementation significantly increased myocardial content of malonaldehydes and hydroxyalkenals compared to the control and ARA groups (p<0.05), and showed a strong trend toward being higher than the DHA group (p = 0.071).

With respect to OS, we observed a statistically significantly higher OS probability in patients with low S100B concentrations (p = 0.0094) and a strong trend of a longer OS in patients with non-elevated LDH levels (p = 0.071) ( Supplementary Figures S1C, S1D ).

An analysis of CLTI patients demonstrated that there was no significant difference between RC 4-5 and RC 6 patients in terms of late mortality, but patients with RC 6 had a strong trend toward higher risk for all-cause death (RC 4-5 vs RC 6: HR 0.59, 95% CI 0.33 to 1.05, p=0.071).

Clinicopathological analysis revealed that higher ASNS expression was associated with distant metastasis (M1 stage, p = 0.034), while higher MET expression showed a strong trend toward association with M1 stage ( p = 0.071) (Tables S7 and S8 ).

In a multivariable regression model, the mortality hazard ratio (HR) for long term mortality remained significant for patients with no/delayed recovery AKI (HR 7.76, 95% CI 4.69 to 12.86, p < 0.001), and a strong trend among patients with resolving AKI (HR 2.09, 95% CI 0.933–4.687, p = 0.071).

There was a strong trend for a positive correlation between acquisition-day CS 5 freezing and freezing during the CS on CS retrieval ( r = 0.593, P = 0.071).